- Home
- DBI vs NVCT Comparison
DBI vs NVCT Comparison
Compare DBI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- NVCT
- Stock Information
- Founded
- DBI 1991
- NVCT 2020
- Country
- DBI United States
- NVCT United States
- Employees
- DBI N/A
- NVCT N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- DBI Consumer Discretionary
- NVCT Health Care
- Exchange
- DBI Nasdaq
- NVCT Nasdaq
- Market Cap
- DBI 178.0M
- NVCT 184.9M
- IPO Year
- DBI 1991
- NVCT 2022
- Fundamental
- Price
- DBI $2.31
- NVCT $8.13
- Analyst Decision
- DBI Hold
- NVCT Strong Buy
- Analyst Count
- DBI 2
- NVCT 3
- Target Price
- DBI $3.50
- NVCT $17.00
- AVG Volume (30 Days)
- DBI 2.1M
- NVCT 97.5K
- Earning Date
- DBI 06-10-2025
- NVCT 08-05-2025
- Dividend Yield
- DBI 8.73%
- NVCT N/A
- EPS Growth
- DBI N/A
- NVCT N/A
- EPS
- DBI N/A
- NVCT N/A
- Revenue
- DBI $2,949,575,000.00
- NVCT N/A
- Revenue This Year
- DBI N/A
- NVCT N/A
- Revenue Next Year
- DBI $2.45
- NVCT N/A
- P/E Ratio
- DBI N/A
- NVCT N/A
- Revenue Growth
- DBI N/A
- NVCT N/A
- 52 Week Low
- DBI $2.18
- NVCT $4.44
- 52 Week High
- DBI $8.45
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- DBI 32.89
- NVCT 37.24
- Support Level
- DBI $2.17
- NVCT $8.79
- Resistance Level
- DBI $2.44
- NVCT $9.30
- Average True Range (ATR)
- DBI 0.25
- NVCT 0.50
- MACD
- DBI -0.13
- NVCT -0.11
- Stochastic Oscillator
- DBI 6.87
- NVCT 12.43
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.